NCT00792571View on ClinicalTrials.gov

An Open-Label Extension of BPS-MR-PAH-201 in Pulmonary Arterial Hypertension (PAH) Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

February 28, 2009

Primary Completion Date

November 30, 2013

Study Completion Date

November 30, 2013

Conditions
Pulmonary Arterial Hypertension
Interventions
DRUG

Beraprost Sodium Modified Release

Trial Locations (6)

15212

Allegheny General Hospital, Pittsburgh

90502

Harbor-UCLA Medical Center, Torrance

75390-8550

UTSW Medical Center Dallas, Dallas

Unknown

Universite Libre de Bruxelles, Brussels

Gastuisberg University Hospital, Leuven

Mater Misericordiae University Hospital Ltd., Dublin

Sponsors
All Listed Sponsors
lead

Lung Biotechnology PBC

INDUSTRY

NCT00792571 - An Open-Label Extension of BPS-MR-PAH-201 in Pulmonary Arterial Hypertension (PAH) Patients | Biotech Hunter | Biotech Hunter